SRI, as one of NIH’s leading preclinical partners, has a long history of rapid response to critical issues like COVID-19.
SRI awarded $107 million NIAID-DAIDS contract to provide preclinical services for HIV therapeutics
MENLO PARK, Calif., November 23, 2020 — SRI International has been awarded a contract of up to $107 million from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS (NIAID-DAIDS) to support basic and pre-clinical research and therapeutic product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis […]
SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products
MENLO PARK, Calif.—October 28, 2020— SRI International has been awarded a Biological Testing Facility (BTF) contract of up to $40 million from the Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD) to complete discovery and preclinical development of new contraceptive compounds. Under the five-year contract, SRI is responsible for all preclinical support […]